Enochian Biosciences, Inc.
ENOB · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.08 | 0.03 | -0.00 | -0.00 |
| FCF Yield | -1.83% | -4.41% | -37,027,653.51% | -15.52% |
| EV / EBITDA | -2.48 | -3.11 | -0.09 | -0.00 |
| Quality | ||||
| ROIC | 1,690.77% | -60.13% | -74.01% | -145.76% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.04 | 0.14 | 0.30 | 0.14 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 28.68% | 100.00% | -75,007,550.52% | 23.82% |
| Safety | ||||
| Net Debt / EBITDA | -0.06 | -0.04 | -0.09 | 0.00 |
| Interest Coverage | -260.40 | 80.75 | 66.44 | -311.33 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |